INS and type 1 diabetes mellitus: These results indicate that a single oral dose of ABA, administered together with s.c. insulin, improves glycemic control by prolonging the reduction in glycemia after insulin administration; this effect occurs both under conditions of increased (300 mg/dL) and excess (>500 mg/dL) fasting glycemia, i.e., in the presence or absence, respectively, of residual endogenous insulin production after T1D induction.